Novo Nordisk, the maker of Ozempic, has achieved a significant milestone: AI is now reliable enough to produce sensitive regulatory documents, with human oversight. With Anthropic's Claude 3.5 Sonnet, they've slashed document drafting time from 15 weeks to just 10 minutes through a collaborative process.

Ozempic Maker Says AI Is Finally Reliable Enough to Produce Sensitive Documents

By Aaron Holmes and Jon Victor

Give yourself an advantage with a Pro subscription, granting you access to these exclusive benefits:

	Industry-specific org charts with reporting lines for 3,000+ executives and directors across a growing list of over 60 companies
	Proprietary databases offering previously unreported insights into startup funding, investors, and more. This includes our Cloud, Chip, and AI Databases
	IPO Tracker that maps out startups on the verge of going public and performance of recent IPOs
	Exclusive events & live conversations where you can engage with experts and exchange ideas with peers
	Weekly Pro Newsletter that features the biggest updates to our data to keep you up-to-date on evolving trends
	Subscriber surveys that create transparency for industry sentiment across today's most relevant topics

Popular articles

The Information Subscriber Council

Comcast NBCUniversal LIFT Labs: Partnering with startups at every stage!

Virtusa: Perspectives with Virtusa

Learn more